XTRA:SRT3Life Sciences
Assessing Sartorius (XTRA:SRT3) Valuation After €140 Million Freiburg Expansion In Cell And Gene Therapy
Sartorius (XTRA:SRT3) has opened a new €140 million competence center in Freiburg for quality critical materials used in cell and gene therapies, more than doubling local manufacturing capacity.
See our latest analysis for Sartorius.
Investors have responded positively to the Freiburg expansion, with the stock showing a 12.85% 1 month share price return and 5.19% 3 month share price return, while the 1 year total shareholder return of 16.56% contrasts with weaker 3 and 5 year outcomes.
If...